Journal for ImmunoTherapy of Cancer (Nov 2020)

837 Interleukin-10 drives the development of T regulatory type 1 (Tr1) cells and is a target for immunotherapy

Yanchun Ma,
Vera Bauer,
Tanja Riedel,
Thomas Hofer,
Martin Roecken,
Ralph Mocikat

Affiliations

Yanchun Ma: 1Helmholtz-Zentrum Muenchen, Munich, Germany
Vera Bauer: 1Helmholtz-Zentrum Muenchen, Munich, Germany
Tanja Riedel: 1Helmholtz-Zentrum Muenchen, Munich, Germany
Thomas Hofer: 1Helmholtz-Zentrum Muenchen, Munich, Germany
Martin Roecken: 2Eberhard-Karls-Universitaet Tuebingen, Tuebingen, Germany
Ralph Mocikat: 1Helmholtz-Zentrum Muenchen, Munich, Germany

DOI: https://doi.org/10.1136/jitc-2020-SITC2020.0837
Journal volume & issue: Vol. 8, no. Suppl 3

Abstract

No abstracts available.

Published in Journal for ImmunoTherapy of Cancer

ISSN: 2051-1426 (Online)
Publisher: BMJ Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://jitc.bmj.com

About the journal